Raw data of the patients. Patient characteristics and follow-up data exists. (XLSX 24Â kb
Figure S2. Dose–volume histograms of the rectum. (A) Dose–volume histograms (DVHs) of the rectum in ...
Additional file 1: Appendix 1. BC CANCER PROVINCIAL SABR ORGAN-AT-RISK (OAR) CONSTRAINTS. Appendix 2...
Table S1. Patient-specific dosimetry for the five male subjects included in the study (1-h urinary v...
Raw data of the patients. Patient characteristics and follow-up data exists. (XLSX 16Â kb
Raw data of the treated lesions. Lesion characteristics and follow-up data exists. (XLSX 15Â kb
Dose constraints used for SABR-5 trial. These are based on the AAPM TG 101, SABR-COMET, SC-24 trial...
Table S1. Association between hippocampus dose and neurocognitive test deterioration. (DOCX 20Â kb
Quality volume histograms of the five patients for planning phase I. (DOCX 116 kb
Table S1. Eligible studies list. Table S2. Study list that containing patients number receiving post...
images of individual dose volume histograms and dose distributions of patients. (DOCX 15022 kb
Table S1. Target Dose and Volume Data by Individual Patient. CTV- clinical target volume; PTV-I – in...
Table S1. Dose fractions of C-ion RT and the number of patients with morbidities for each prescripti...
Figure. S1. Figure showing the isodose line of 20âGy (outlined in yellow) and 5âGy (outlined in ...
Table S1. Characteristics of unmatched and matched treatment groups; The table shows the characteris...
Table S1. Patientâs characteristics in 3 head and neck squamous cell cancer cohorts. (DOCX 18Â kb
Figure S2. Dose–volume histograms of the rectum. (A) Dose–volume histograms (DVHs) of the rectum in ...
Additional file 1: Appendix 1. BC CANCER PROVINCIAL SABR ORGAN-AT-RISK (OAR) CONSTRAINTS. Appendix 2...
Table S1. Patient-specific dosimetry for the five male subjects included in the study (1-h urinary v...
Raw data of the patients. Patient characteristics and follow-up data exists. (XLSX 16Â kb
Raw data of the treated lesions. Lesion characteristics and follow-up data exists. (XLSX 15Â kb
Dose constraints used for SABR-5 trial. These are based on the AAPM TG 101, SABR-COMET, SC-24 trial...
Table S1. Association between hippocampus dose and neurocognitive test deterioration. (DOCX 20Â kb
Quality volume histograms of the five patients for planning phase I. (DOCX 116 kb
Table S1. Eligible studies list. Table S2. Study list that containing patients number receiving post...
images of individual dose volume histograms and dose distributions of patients. (DOCX 15022 kb
Table S1. Target Dose and Volume Data by Individual Patient. CTV- clinical target volume; PTV-I – in...
Table S1. Dose fractions of C-ion RT and the number of patients with morbidities for each prescripti...
Figure. S1. Figure showing the isodose line of 20âGy (outlined in yellow) and 5âGy (outlined in ...
Table S1. Characteristics of unmatched and matched treatment groups; The table shows the characteris...
Table S1. Patientâs characteristics in 3 head and neck squamous cell cancer cohorts. (DOCX 18Â kb
Figure S2. Dose–volume histograms of the rectum. (A) Dose–volume histograms (DVHs) of the rectum in ...
Additional file 1: Appendix 1. BC CANCER PROVINCIAL SABR ORGAN-AT-RISK (OAR) CONSTRAINTS. Appendix 2...
Table S1. Patient-specific dosimetry for the five male subjects included in the study (1-h urinary v...